Thirteen states cover GLP-1 drugs through their Medicaid programs, and others are considering following suit
Weight fluctuates by 2 to 5 pounds daily based on water retention, food volume, sodium intake, and hormonal status
Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition. The A4PCs guidance leaves no room for interpretation on this point
In subjects with T2DM, weekly administration of tirzepatide at doses of 5 mg, 10 mg, or 15 mg was associated with greater weight loss compared to placebo ( 6.3 kg, 8.4 kg, and 9.4 kg, respectively), and 1.7 kg, 4.8 kg, and 7.2 kg greater weight loss compared to selective GLP-1 receptor agonists, demonstrating a dose-dependent effect sustained for up to 2 years [48]